Merck & Co. Patent-Cliff Exposure & CMS Drug Spending Portfolio

Merck & Co. (Rahway, NJ): 59 reconciled FDA prescription therapies (76.5% 2025 to 2030 cliff risk), $8.38B 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterRahway, NJ
Reconciled FDA Portfolio Therapies59
2025 to 2030 Patent-Cliff Revenue Exposure76.5%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$8.38B
2024 Medicare Part D Spend$6.30B
2024 Medicaid Spend$2.08B
California HCAI SB 17 Filings24 WAC filings (max 32.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.